Benjamin Bakall

3 weeks ago | ophthalmologytimes.com | Benjamin Bakall |Sydney M Crago

The TEASE-1 clinical trial examined gildeuretinol in 50 patients with Stargardt disease. Data from this trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which was held in Salt Lake City, Utah. Ophthalmology Times caught up with Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants, and Clinical Assistant Professor at University of Arizona College of Medicine – Phoenix.

1 month ago | healio.com | Benjamin Bakall |Alex Young |Eamon Dreisbach |Anthony DeFino

SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Benjamin Bakall, MD, PhD, discusses 2-year data from the TEASE-1 study investigating the safety and efficacy of gildeuretinol in patients with Stargardt disease. The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a significant reduction in growth of the area of atrophy.